Chronic orbital inflammation

Summary

Chronic orbital inflammation (MONDO:0001849) is a disease. A subtype of disease of orbital part of eye adnexa — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	chronic orbital inflammation
Mondo ID	MONDO:0001849
DOID	DOID:1397
SNOMED CT	44729001
UMLS	C0155261
MedGen	509880
Is cancer (heuristic)	no

Disease family

This is a subtype of disease of orbital part of eye adnexa. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye adnexa disorder › disease of orbital part of eye adnexa › chronic orbital inflammation

Related subtypes (8): enophthalmos, acute orbital inflammation, endocrine exophthalmos, lateral displacement of eye, intermittent proptosis, pulsating exophthalmos, orbital cyst, constant exophthalmos

Subtypes (2): orbital granuloma, orbital pseudotumor

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.